Filing Flows › Insulet (PODD) › Q3 2026
Insulet (PODD) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Insulet (PODD) reported revenue of $842M for the third quarter 2026 (Q3 2026), +19% from a year earlier and +5% from the quarter before. Operating margin was 22.5%, net earnings $141M (16.8% of revenue).
Insulet, Q3 2026: revenue $842M (+19% year over year), operating margin 22.5%, net earnings $141M, operating cash flow $124M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $842M | +5% | +19% |
| Gross profit | $632M | +12% | +24% |
| Operating profit | $190M | +46% | +61% |
| Net earnings | $141M | +49% | +61% |
| Operating cash flow | $124M | +40% | -2% |
| Free cash flow | $66.4M | +19% | -34% |
What changed
Revenue was $842.0M in Q3 2026, up 19% year over year and up 5% from the previous quarter. U.S. was the largest line at 68% of revenue. U.S. added $73.3M year over year (up 15%), 54% of the total change. Drug Delivery declined 23%.
Gross margin was 75.1%, up 2.8 points from Q3 2025. Operating profit was $189.8M, a 22.5% margin (up 5.9 points year over year). Of the extra revenue versus Q3 2025, 53% reached operating profit, above the 17% margin then. Operating expenses grew 13% against revenue growth of 19%. The fastest-growing cost line was Research & development (+19%). Net earnings were $141.1M, up 61% year over year. The effective tax rate was 20.4%.
Operating cash flow was $123.5M (down 2% year over year), 88% of net earnings. Non-cash charges added back $28.2M of depreciation and amortization and $20.6M of share-based compensation. Working capital and other items used $66.4M. Capital expenditures of $57.1M left free cash flow of $66.4M.
Questions
What was Insulet's revenue in the third quarter 2026?
Insulet (PODD) reported revenue of $842M for the third quarter 2026 (Q3 2026), +19% from a year earlier and +5% from the quarter before.
Was Insulet profitable in the third quarter 2026?
Operating profit was $190M (22.5% of revenue) and net earnings $141M.
Source: Insulet 10-Q on SEC EDGAR.